Probiotics in the treatment of severe acute pancreatitis:a Meta-analysis of randomized controlled trials
10.3969/j.issn.1671-8348.2017.19.024
- VernacularTitle:益生菌治疗重症急性胰腺炎的随机对照试验Meta分析
- Author:
Maolin WANG
;
Zhu CHEN
;
Bimin FENG
;
Guojun WANG
- Keywords:
probiotics;
severe acute pancreatitis;
Meta-analysis
- From:
Chongqing Medicine
2017;46(19):2672-2676
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematically evaluate the safety and efficacy of probiotics in the treatment of severe acute pancreatitis (SAP).Methods The randomized controlled trials (RCTs) for studying probiotics in the treatment of SAP were retrieved from databases,including PubMed,Embase,Cochrane Library,Medline,Chinese Biomedical Literature Database (CBM),Chinese science and technology journal full-text database (VIP),China journal full-text database (CNKI),Wanfang academic journal fulltext database.The methodological quality of included literatures was evaluated,and statistical analysis was performed via RevMan5.3 software.Results A total of 12 pieces of RCT literatures including 910 cases of patients with SAP were included.The results of meta analysis indicated that no statistically significant difference was found in the mortality [RR =0.97,95 ％ CI(0.63,1.49),P=0.88],the incidence rate of multiple organ dysfunction [RR =0.72,95 ％ CI(0.49,1.06),P=0.10] and the incidence rate of pancreas-related infections [RR=0.76,95 ％ CI(0.54,1.07),P=0.12] between the probiotics group and the control group;while there were statistically significant differences in the length of hospital stay [MD =-3.74,95 ％ CI(-6.37,-1.12),P=0.005] and the incidence rate of intestinal ischemia necrosis [RR=11.39,95 ％ CI(1.5,86.4),P =0.02],Conclusion Probiotics could not improve clinical outcomes of patients with SAP,and may increase risk for intestinal ischemic necrosis.However,it could shorten the length of hospital stay.
